Angiogenesis—the formation of new blood vessels from pre-existing vasculature—is a fundamental process in both development and disease. In cancer, tumors exploit angiogenesis to sustain oxygen and nutrient supply, facilitate growth beyond microscopic size, and enable metastatic dissemination. Therapeutic angiogenesis inhibition targets key signaling pathways that drive this vascular remodeling, aiming to starve tumors, normalize aberrant tumor vasculature, and reduce metastatic potential.
The physiologic basis of angiogenesis involves endothelial cell activation, degradation of basement membrane, endothelial migration and proliferation, and vessel maturation. A central molecular regulator is the vascular endothelial growth factor (VEGF) axis. Tumors and stromal cells upregulate VEGF (and related ligands) in response to hypoxia via hypoxia-inducible factor (HIF) signaling. Activated VEGF binds to VEGF receptors (primarily VEGFR-2) on endothelial cells, triggering downstream pathways such as PI3K/AKT and MAPK, which promote survival and proliferation. In parallel, other pro-angiogenic factors (e.g., angiopoietins/Tie2) and inflammatory mediators amplify the vascular phenotype.
Angiogenesis inhibitors include monoclonal antibodies that sequester VEGF (e.g., bevacizumab) and small-molecule tyrosine kinase inhibitors (TKIs) that block VEGF receptor signaling (e.g., sunitinib, sorafenib, axitinib, pazopanib). By interrupting ligand–receptor interactions or receptor kinase activity, these agents reduce endothelial proliferation and disrupt tumor blood supply. Clinically, efficacy may arise not only from vascular deprivation but also from so-called “vascular normalization”: by pruning ineffective vessels and improving perfusion, drug-induced changes can enhance oxygenation and potentially improve delivery of cytotoxic therapies when combined in selected regimens.
Indications vary by cancer type and agent. Anti-VEGF therapy has demonstrated benefit in several solid tumors and is often used in combination with chemotherapy or immunotherapy. Small-molecule VEGFR TKIs have roles in renal cell carcinoma, hepatocellular carcinoma, and other malignancies depending on molecular rationale and guideline recommendations. Treatment selection requires careful assessment of performance status, baseline blood pressure, cardiovascular risk, proteinuria risk, drug–drug interaction potential, and prior exposure.
Adverse effects reflect on-target effects in normal vasculature. Hypertension is among the most common toxicities and is thought to result from reduced endothelial nitric oxide bioavailability and altered vascular tone, leading to increased systemic vascular resistance. Proteinuria and nephrotic-range events can occur due to glomerular endothelial injury. Bleeding risk may rise, particularly in patients with tumor-related hemorrhage or concurrent anticoagulation, reflecting impaired repair of vascular integrity. Thromboembolic events can also occur, indicating a complex balance between altered coagulation and vascular function.
Wound healing complications are clinically important. Because angiogenesis is necessary for tissue repair, therapy is frequently held perioperatively to reduce risk of dehiscence and impaired healing. Additional toxicities include fatigue, diarrhea, hand–foot skin reaction (more typical of certain TKIs), and hepatotoxicity with transaminase elevations. Rare but serious events such as gastrointestinal perforation, arterial aneurysm/dissection, and congestive heart failure have been reported across drug classes, necessitating heightened vigilance in susceptible patients.
Monitoring strategies are integral to safe use. Baseline assessment typically includes blood pressure, renal function (serum creatinine), urinalysis for protein, and hepatic enzymes. During therapy, blood pressure should be regularly measured with prompt antihypertensive management. Urine protein monitoring is recommended, with dose adjustments or interruptions for significant proteinuria. Renal and hepatic function should be followed at intervals aligned with the specific agent’s safety profile. For patients experiencing concerning symptoms—severe headache, neurologic deficits, chest pain, signs of bleeding, or abdominal pain—urgent evaluation is warranted to rule out uncommon but high-risk complications.
Risk mitigation requires addressing modifiable factors such as uncontrolled hypertension, baseline kidney disease, and medication interactions through CYP metabolism pathways. When combining angiogenesis inhibitors with other systemic therapies, clinicians must consider overlapping toxicities (e.g., myelosuppression from chemotherapy, immune-related effects from immunotherapy) and ensure an evidence-based sequencing strategy.
Overall, angiogenesis inhibitors represent a major pillar of modern oncology, disrupting the VEGF-driven vascular program that tumors depend on. Their benefit is accompanied by characteristic toxicities tied to vascular biology. With structured monitoring and proactive management of adverse effects, these therapies can be delivered more safely, maximizing therapeutic benefit while minimizing morbidity.
Source: @D555555D (via the provided X post context)
David: @SteveKim323 Agreed. The Governing Body is supposed to be authority. They decide. As for Usyk ducking? Nah. He knocked out Dubois, and then Turki (the $$) wanted Rico. What’s Usyk supposed to do? Besides, you get a little grace (as a fan) when you are a 39 year old Champ, in his last. #breaking
— @D555555D May 1, 2026
SHOP AMAZON BEST SELLERS, CLICK TO BUY FROM AMAZON.
SHOP AMAZON BEST SELLERS, CLICK TO BUY FROM AMAZON.
